Clinical Trials
17 trialsNCT04731376 2026-05-26
Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone
Emory University
Phase 1 Active not recruiting
NCT06238479 2026-05-22
EXCEED
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06465069 2026-05-22
NEXUS-01
Eli Lilly and Company
Phase 1 Recruiting
NCT03093909 2026-05-20
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05614739 2026-05-19
FORAGER-1
Eli Lilly and Company
Phase 1 Recruiting
NCT01552434 2026-05-15
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT07566156 2026-05-11
EV-309
Astellas Pharma Inc
Phase 3 Recruiting
NCT05946993 2026-05-01
LIAM Mc
University College Cork
Phase NA Active not recruiting
NCT05726136 2026-04-30
FC-VE
University Hospital, Linkoeping
Phase 4 Recruiting
NCT07558447 2026-04-30
CHEMOVES
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Phase NA Recruiting
NCT03595813 2026-04-21
IMMUNO-SUP
Institut Paoli-Calmettes
Phase NA Completed
NCT03435952 2026-04-16
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03091192 2026-04-14
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Phase 3 Active not recruiting
NCT03288545 2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2 Terminated
NCT03420963 2026-03-20
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT07313891 2026-03-17
BOOST
Relmada Therapeutics, Inc.
Phase 3 Withdrawn
NCT07342517 2026-03-17
RESCUE
Relmada Therapeutics, Inc.
Phase 3 Withdrawn